Back

ChemoMetec guides for 2026/27 revenue of DKK 545-575 million and EBITDA of DKK 300-315

Verifying
  • ChemoMetec approved its 2025/26 annual report and issued 2026/27 guidance.
  • Revenue guidance is DKK 545-575 million, versus DKK 511.1 million in 2025/26.
  • The annual report details guidance assumptions on pages 40-41.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.